Cargando…

A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV

BACKGROUND: The concentration and duration of antibodies (Ab) to SARS-CoV-2 infection predicts the severity of the disease and the clinical outcomes. Older people and those with HIV have impaired immune responses, worse outcomes after SARS-CoV-2 infection, and lower antibody responses after viral in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alcaide, Maria L., Nogueira, Nicholas F., Salazar, Ana S., Montgomerie, Emily K., Rodriguez, Violeta J., Raccamarich, Patricia D., Barreto, Irma T., McGaugh, Angela, Sharkey, Mark E., Mantero, Alejandro M., Rodriguez, Allan E., Beauchamps, Laura, Jones, Deborah L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940197/
https://www.ncbi.nlm.nih.gov/pubmed/35330585
http://dx.doi.org/10.3389/fmed.2022.768138
_version_ 1784672877307494400
author Alcaide, Maria L.
Nogueira, Nicholas F.
Salazar, Ana S.
Montgomerie, Emily K.
Rodriguez, Violeta J.
Raccamarich, Patricia D.
Barreto, Irma T.
McGaugh, Angela
Sharkey, Mark E.
Mantero, Alejandro M.
Rodriguez, Allan E.
Beauchamps, Laura
Jones, Deborah L.
author_facet Alcaide, Maria L.
Nogueira, Nicholas F.
Salazar, Ana S.
Montgomerie, Emily K.
Rodriguez, Violeta J.
Raccamarich, Patricia D.
Barreto, Irma T.
McGaugh, Angela
Sharkey, Mark E.
Mantero, Alejandro M.
Rodriguez, Allan E.
Beauchamps, Laura
Jones, Deborah L.
author_sort Alcaide, Maria L.
collection PubMed
description BACKGROUND: The concentration and duration of antibodies (Ab) to SARS-CoV-2 infection predicts the severity of the disease and the clinical outcomes. Older people and those with HIV have impaired immune responses, worse outcomes after SARS-CoV-2 infection, and lower antibody responses after viral infection and vaccination. This study evaluated an Ab response to SARS-CoV-2 in people with HIV (PWH) and without HIV (HIV-) and its association with age. METHODS: A total of 23 COVID+PWH and 21 COVID+HIV- participants were followed longitudinally for 6 months post-mild COVID-19. Immunoglobin G (IgG) and immunoglobin M (IgM) Ab responses were measured by an in-house developed ELISA. Time points and HIV status interaction were analyzed using Poisson generalized estimating equations, and correlations were analyzed using non-parametric tests. RESULTS: Median age in PWH was 55 years with 28.6% women, while in the HIV- group was 36 years with 60.9% women. The mean time from COVID-19 diagnosis to study enrollment was 16 days for PWH and 11 days for HIV-. The mean CD4+ T-cell count/μl for PWH was 772.10 (±365.21). SARS-CoV-2 IgM and IgG were detected at all time points and Ab response levels did not differ by HIV status (p > 0.05). At entry, age showed a weak direct association with IgG responses (ρ = 0.44, p < 0.05) in HIV- but did not show any association in PWH. Similar associations between age, IgG, and HIV status emerged at day 14 (T1; ρ = 0.50, p < 0.05), 3 months (T3; ρ = 0.50, p < 0.05), and 6 months visit (T4; ρ = 0.78, p < 0.05) in the HIV- group. CONCLUSION: The Ab responses in the 6-month post-SARS-CoV-2 infection did not differ by HIV status, though a positive association was found between age and Ab response in older PWH. Results suggest that immune protection and vaccine responses are similar for PWH than for those without HIV infection.
format Online
Article
Text
id pubmed-8940197
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89401972022-03-23 A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV Alcaide, Maria L. Nogueira, Nicholas F. Salazar, Ana S. Montgomerie, Emily K. Rodriguez, Violeta J. Raccamarich, Patricia D. Barreto, Irma T. McGaugh, Angela Sharkey, Mark E. Mantero, Alejandro M. Rodriguez, Allan E. Beauchamps, Laura Jones, Deborah L. Front Med (Lausanne) Medicine BACKGROUND: The concentration and duration of antibodies (Ab) to SARS-CoV-2 infection predicts the severity of the disease and the clinical outcomes. Older people and those with HIV have impaired immune responses, worse outcomes after SARS-CoV-2 infection, and lower antibody responses after viral infection and vaccination. This study evaluated an Ab response to SARS-CoV-2 in people with HIV (PWH) and without HIV (HIV-) and its association with age. METHODS: A total of 23 COVID+PWH and 21 COVID+HIV- participants were followed longitudinally for 6 months post-mild COVID-19. Immunoglobin G (IgG) and immunoglobin M (IgM) Ab responses were measured by an in-house developed ELISA. Time points and HIV status interaction were analyzed using Poisson generalized estimating equations, and correlations were analyzed using non-parametric tests. RESULTS: Median age in PWH was 55 years with 28.6% women, while in the HIV- group was 36 years with 60.9% women. The mean time from COVID-19 diagnosis to study enrollment was 16 days for PWH and 11 days for HIV-. The mean CD4+ T-cell count/μl for PWH was 772.10 (±365.21). SARS-CoV-2 IgM and IgG were detected at all time points and Ab response levels did not differ by HIV status (p > 0.05). At entry, age showed a weak direct association with IgG responses (ρ = 0.44, p < 0.05) in HIV- but did not show any association in PWH. Similar associations between age, IgG, and HIV status emerged at day 14 (T1; ρ = 0.50, p < 0.05), 3 months (T3; ρ = 0.50, p < 0.05), and 6 months visit (T4; ρ = 0.78, p < 0.05) in the HIV- group. CONCLUSION: The Ab responses in the 6-month post-SARS-CoV-2 infection did not differ by HIV status, though a positive association was found between age and Ab response in older PWH. Results suggest that immune protection and vaccine responses are similar for PWH than for those without HIV infection. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8940197/ /pubmed/35330585 http://dx.doi.org/10.3389/fmed.2022.768138 Text en Copyright © 2022 Alcaide, Nogueira, Salazar, Montgomerie, Rodriguez, Raccamarich, Barreto, McGaugh, Sharkey, Mantero, Rodriguez, Beauchamps and Jones. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Alcaide, Maria L.
Nogueira, Nicholas F.
Salazar, Ana S.
Montgomerie, Emily K.
Rodriguez, Violeta J.
Raccamarich, Patricia D.
Barreto, Irma T.
McGaugh, Angela
Sharkey, Mark E.
Mantero, Alejandro M.
Rodriguez, Allan E.
Beauchamps, Laura
Jones, Deborah L.
A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
title A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
title_full A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
title_fullStr A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
title_full_unstemmed A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
title_short A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
title_sort longitudinal analysis of sars-cov-2 antibody responses among people with hiv
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940197/
https://www.ncbi.nlm.nih.gov/pubmed/35330585
http://dx.doi.org/10.3389/fmed.2022.768138
work_keys_str_mv AT alcaidemarial alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT nogueiranicholasf alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT salazaranas alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT montgomerieemilyk alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT rodriguezvioletaj alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT raccamarichpatriciad alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT barretoirmat alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT mcgaughangela alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT sharkeymarke alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT manteroalejandrom alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT rodriguezallane alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT beauchampslaura alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT jonesdeborahl alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT alcaidemarial longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT nogueiranicholasf longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT salazaranas longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT montgomerieemilyk longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT rodriguezvioletaj longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT raccamarichpatriciad longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT barretoirmat longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT mcgaughangela longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT sharkeymarke longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT manteroalejandrom longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT rodriguezallane longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT beauchampslaura longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv
AT jonesdeborahl longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv